Mankind Pharma (MANKIND.NS) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

MANKIND.NS · Stock Price

INR 2,375.20-33.00 (-1.37%)

Market Cap: $10.6B

Historical price data

Market Cap: $10.6BPipeline: 2 drugs (1 Phase 3)Patents: 16Founded: 1995Employees: 10,000+HQ: New Delhi, India

Sector Ranking#13 in Small Molecule Drugs

Overview

Mankind Pharma is a dominant Indian pharmaceutical player with a mission to deliver affordable and accessible healthcare across the nation. Founded in 1995, it has achieved market leadership through deep penetration of underserved rural and semi-urban markets, supported by a company-owned distribution infrastructure. Its strategy is built on a diversified business model spanning formulations, consumer healthcare, APIs, and agritech, backed by significant R&D capabilities and manufacturing scale. The company is publicly traded and is recognized for its operational excellence and commitment to serving 'Bharat'.

Chronic (CVS, CNS, Anti-diabetic)Acute (Anti-infectives)GynecologyConsumer HealthcareVeterinary

Technology Platform

Vertically integrated platform encompassing novel drug discovery (NDDR), complex generic formulation development, API synthesis, biotechnology, and a proprietary, company-owned distribution network for deep rural penetration.

Pipeline

2

2 drugs in pipeline1 in Phase 3

Drug	Indication	Stage	Watch
Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - L...	Glaucoma, Open-Angle	Phase 3
MKP10241 + Placebo	Type 2 Diabetes Mellitus (T2DM)	Phase 2

Funding History

1

IPOUndisclosedUndisclosedMay 15, 2023

FDA Approved Drugs

1

VARENICLINE TARTRATEANDAAug 1, 2023

Opportunities

The primary opportunity lies in capturing the underpenetrated healthcare demand in India's rural and semi-urban markets, supported by rising incomes and health awareness.

Additionally, global supply chain shifts present a major growth avenue for its API business, while its pipeline of complex generics and biosimilars offers margin expansion potential.

Risk Factors

Key risks include stringent government price controls on essential drugs, intense competition in the domestic generics market pressuring margins, and the inherent uncertainty and high cost associated with its novel drug discovery and biosimilar development programs.

Competitive Landscape

Mankind competes with large domestic pharma companies (Sun Pharma, Cipla) and multinationals, but its defensible moat is its unparalleled direct distribution network in Tier II-IV cities and rural India. This grassroots strength is difficult for competitors to replicate quickly.